----item----
version: 1
id: {23F6EEA7-4138-4B5B-8BEB-B65A0A7C39A3}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/20/Basileas Ceftobiprole Dubbed Qualified Infectious Disease Product
parent: {9272B77E-1398-4EF1-A77A-17C397C8C6D1}
name: Basileas Ceftobiprole Dubbed Qualified Infectious Disease Product
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 43b5ac10-c3a9-4227-b055-20dc326c1033

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 66

Basilea's Ceftobiprole Dubbed Qualified Infectious Disease Product
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 65

Basileas Ceftobiprole Dubbed Qualified Infectious Disease Product
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2801

<p>Basilea Pharmaceutica's ceftobiprole was designated by the FDA as a qualified infectious disease product &ndash; a status under which the drug is eligible for an additional five years of market exclusivity if approved for the indications.</p><p>Ceftobiprole is broad-spectrum intravenous cephalosporin antibiotic being developed for use against certain Gram-positive and Gram-negative bacteria, including clinical isolates that are resistant to existing therapies.</p><p>Basilea is developing ceftobiprole in the US as a treatment for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.</p><p>The drug currently is approved for use in adults in 13 European countries as a treatment for community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia.</p><p>With the QIDP status, ceftobiprole is eligible to receive a special priority review intended to accelerate its regulatory process.</p><p><a href="http://www.scripintelligence.com/policyregulation/FDA-adds-3-new-qualifying-pathogens-for-GAIN-incentives-352156" target="_new">QIDP</a> was <a href="http://www.scripintelligence.com/home/All-too-easy-Obama-signs-US-FDA-user-fee-bill-without-fanfare-332602" target="_new">created</a> in 2012 under the <i>Generating Antibiotic Incentives Now (GAIN) Act</i> to provide incentives for drug makers to pursue antibiotic against some of the deadliest infections,</p><p>John Farley, deputy director of the FDA's Office of Antimicrobial Products, said so far, told <i>Scrip</i> the agency has granted QIDP designation 78 times to 53 unique molecular entities under development. </p><p>Six antibacterial medicines with the QIDP designation have been approved in the US since the GAIN Act was passed: Actavis' <a href="http://www.scripintelligence.com/home/Actavis-antibiotic-combo-Avycaz-OKd-for-2-infections-356951" target="_new">Avycaz</a> (ceftazidime-avibactam) and <a href="http://www.scripintelligence.com/home/APPROVED-Duratas-Dalvance-1st-QIDP-antibiotic-OKd-for-US-market-351986" target="_new">Dalvance</a> (dalvabancin), Astellas' <a href="http://www.scripintelligence.com/policyregulation/Astellas-wins-FDA-nod-for-antifungal-Cresemba-357117" target="_new">Cresemba</a> (isavuconazonium sulfate), The Medicines Company's <a href="http://www.scripintelligence.com/home/Medicines-single-dose-ABSSSI-drug-Orbactiv-OKd-353227" target="_new">Orbactiv</a> (oritavancin) and Merck's <a href="http://www.scripintelligence.com/home/FDA-OKs-Cubists-Sivextro-another-antibiotic-GAIN-352461" target="_new">Sivextro</a> (tedizolid) and <a href="http://www.scripintelligence.com/home/Cubist-wins-FDA-nod-for-antibiotic-Zerbaxa-355772" target="_new">Zerbaxa</a> (ceftolozane/tazobactam).</p><p><p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 245

<p>Basilea Pharmaceutica's ceftobiprole was designated by the FDA as a qualified infectious disease product &ndash; a status under which the drug is eligible for an additional five years of market exclusivity if approved for the indications.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 65

Basileas Ceftobiprole Dubbed Qualified Infectious Disease Product
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150520T110440
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150520T110440
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150520T110440
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029493
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 66

Basilea's Ceftobiprole Dubbed Qualified Infectious Disease Product
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 12

Face-to-Face
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359845
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042434Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

43b5ac10-c3a9-4227-b055-20dc326c1033
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042434Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
